Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.28
    -0.12 (-1.62%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Maravai Lifesciences Holdings Inc (MRVI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Maravai Lifesciences Holdings (MRVI) has a market cap of $1.96B and an enterprise value of $2.03B. It kept -54.00% of revenue as net income over the last 12 months. Its share count is up 3.03% from a year earlier.

    Total Valuation

    Enterprise value is 3.78% above the market cap, as debt exceeds cash.

    Market Cap$1.96B
    Enterprise Value$2.03B
    Latest price (Nov 17, 2026)$7.28

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.72% in the quarter ended Sep 30, 2026 and grew 2.62% a year over 2 years.

    Shares Outstanding149.07M
    Shares Change (YoY)+3.03%
    Shares Change (QoQ)+0.72%
    Share Count Growth (2Y CAGR)+2.62%

    Valuation Ratios

    Sales and book value multiples are 5.1x and 5.5x. Its year-end P/S ranged from 2.1x to 9.5x from 2020 to 2025.

    P/S Ratio5.1x
    Forward P/S9.1x
    P/B Ratio5.5x

    Valuation history and multiples

    Price Statistics

    The stock is up 100.00% over 52 weeks and trades 1.62% below its 50-day average.

    Beta (1Y)1.65
    52-Week Change+100.00%
    1-Month Change+4.15%
    3-Month Change+0.83%
    6-Month Change+72.51%
    5-Year Change-81.53%
    Total Return (1Y)+100.00%
    Total Return (3Y CAGR)+13.19%
    Total Return (5Y CAGR)-28.01%
    Return vs SPY (1Y)+89.55%
    Max Drawdown (1Y)-29.60%
    Max Drawdown (3Y)-84.83%
    Sharpe Ratio (1Y)1.05
    Correlation with SPY (1Y)0.34
    50-Day Average$7.40
    200-Day Average$5.47
    52-Week Range$2.80 to $9.42
    RSI (14 Days)46.7
    Average Volume (20 Days)2.19M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.66x current liabilities, and total debt is 0.75x shareholder equity.

    Current Ratio4.66x
    Quick Ratio3.35x
    Debt / Equity0.75x
    Interest Coverage13.86x

    Returns and Efficiency

    Return on invested capital is -28.26% over the last 12 months, against a 5-year average of 13.87%.

    Return on Equity (ROE)-58.72%
    Return on Assets (ROA)-19.17%
    Return on Invested Capital (ROIC)-28.26%
    Return on Capital Employed (ROCE)-17.16%
    ROE (5Y Average)3.41%
    ROA (5Y Average)-3.81%
    ROIC (5Y Average)13.87%
    Asset Turnover0.29x
    Inventory Turnover3.07x
    Receivables Turnover7.49x
    Cash Conversion Cycle148 days

    Scores

    MRVI has an Altman Z-Score of 2.52, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score2.52
    Altman Z ZoneGrey
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $213.00M over the last 12 months is up 10.68% from the 12 months before.

    Revenue$213.00M
    Revenue Growth (YoY)+10.68%
    Gross Profit$83.39M
    Operating Income-$96.66M
    Pretax Income-$115.41M
    Net Income-$115.02M
    EBITDA-$41.91M
    EBIT-$97.28M
    Reported EPS (TTM)-$0.18

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 32.64% of the $600.07M in total assets.

    Cash and Equivalents$73.02M
    Total Debt$147.18M
    Net Debt$74.16M
    Net Debt Per Share$0.50
    Working Capital$120.94M
    Shareholder Equity$195.89M
    Book Value Per Share$1.31
    Tangible Book Value-$64.51M
    Total Assets$600.07M
    Total Liabilities$259.90M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $7.44M of capital spending, operating cash flow left -$12.54M of free cash flow.

    Operating Cash Flow-$5.10M
    Capital Expenditures$7.44M
    Free Cash Flow-$12.54M
    FCF Per Share-$0.08
    Depreciation and Amortization$55.37M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -45.38%, against a 5-year average of -16.67%.

    Gross Margin39.15%
    Operating Margin-45.38%
    Pretax Margin-54.19%
    Net Margin-54.00%
    EBITDA Margin-19.68%
    EBIT Margin-45.67%
    FCF Margin-5.89%
    Gross Margin (5Y Average)54.38%
    Operating Margin (5Y Average)-16.67%
    Net Margin (5Y Average)-31.60%

    Growth

    Revenue fell 40.53% a year over 3 years.

    Revenue Growth (3Y CAGR)-40.53%
    Revenue Growth (5Y CAGR)-8.15%
    Book Value Per Share Growth (2Y CAGR)-31.87%

    Revenue and profit by year

    Dividends and Yields

    MRVI does not pay a dividend. Its free cash flow yield is -1.16%.

    FCF Yield-1.16%
    Buyback Yield0.12%
    Shareholder Yield0.12%

    Peer Position

    Against 8 similar companies, MRVI has the 5th highest P/S.

    P/S Ratio5.1x vs 4.2x median
    ROIC-28.26% vs -48.17% median
    Revenue Growth (Trailing 4 Quarters, YoY)+10.68% vs +19.79% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.95% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.95%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRVI

    What is MRVI's market cap?

    Maravai Lifesciences Holdings has a market cap of $1.96B. Its enterprise value, which adds debt and subtracts cash, is $2.03B.

    How many shares of MRVI are outstanding?

    Maravai Lifesciences Holdings has 149.07M shares outstanding. The count is up 3.03% from a year earlier.

    Does MRVI pay a dividend?

    No. Maravai Lifesciences Holdings does not pay a dividend.

    How much debt does MRVI have?

    Maravai Lifesciences Holdings has $147.18M of total debt and $73.02M of cash and equivalents, a net debt position of $74.16M.